Vol 13: Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) - a prospective, placebo-controlled, double-blind study.Reportar como inadecuado



 Vol 13: Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) - a prospective, placebo-controlled, double-blind study.


Vol 13: Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) - a prospective, placebo-controlled, double-blind study. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 13: Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) - a prospective, placebo-controlled, double-blind study.
This article is from BMC Infectious Diseases, volume 13.AbstractBackground: Heparin Binding Protein (HBP) is released to blood circulation from activated neutrophils in bacterial infections. It is a potential inducer of vascular leakage and precludes the development of septic shock. Filgrastim induces the production of new neutrophils and modulates their bacterial-killing activity. We evaluated the effect of filgrastim on HBP –concentrations in critically ill patients with acute respiratory failure. Methods: 59 critically ill patients with acute respiratory failure were included in this randomised, double-blind, placebo-controlled study of filgrastim 300 micrograms-day or corresponding placebo for 7 days. Plasma samples were drawn on baseline, day 4 and day 7. HBP –concentrations, absolute leukocyte and neutrophil counts were measured. Results: The median IQR HBP concentrations were 23.6 ng-ml 13.9-43.0 ng-ml, 25.1 ng-ml 17.7-35.5 ng-ml and 15.9 ng-ml 12.6-20.7 ng-ml in patients receiving filgrastim on baseline, day 4 and day 7, respectively. The HBP concentrations in placebo group were 21.6 ng-ml 16.9-28.7 ng-ml, 13.9 ng-ml 12.0-19.5 ng-ml and 17.8 ng-ml 13.6-20.9 ng-ml. At day 4, the filgrastim group had significantly higher HBP –concentrations when compared to placebo group (p 



Autor: Kaukonen, Kirsi-Maija; Herwald, Heiko; Lindbom, Lennart; Pettila, Ville

Fuente: https://archive.org/







Documentos relacionados